- Novavax (NASDAQ:NVAX) announces that 5,500 volunteers have been enrolled in a U.K.-based Phase 3 clinical trial evaluating the safety and immunogenicity of its COVID-19 vaccine candidate NVX-CoV2373. Enrollment, now expanded to 15,000 (from 9,000) subjects, should be completed by the end of November.
- Preliminary data may be available as early as next quarter.
- A pivotal U.S. study should launch by the end of next month.
- On Friday, October 30, it will present new reactogenicity data from its ongoing Phase 1/2 study during the CDC's Advisory Committee on Immunization Practices meeting.
- https://seekingalpha.com/news/3626424-novavax-advancing-late-stage-study-of-covidminus-19-vaccine
Tuesday, October 27, 2020
Novavax advancing late-stage study of COVID-19 vaccine
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.